businesspress24.com - Kane Biotech Announces Board Members
 

Kane Biotech Announces Board Members

ID: 1368547

(firmenpresse) - WINNIPEG, MANITOBA -- (Marketwired) -- 06/25/15 -- Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce that the Company''s Annual and Special Meeting of shareholders held on June 22, 2015 (the "Meeting"), the following individuals have been elected to the board of directors; Philip Renaud (Chairman), Dr. Arvind Joshi, Mark Nawacki, Dr. Sarah Prichard and Mark Ahrens-Townsend. Each Director is to serve for a term of one year or until their successors are elected or appointed.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.

Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™ and Coactiv+™ are registered trademarks of Kane Biotech Inc. All Rights Reserved 2015.



Contacts:
Kane Biotech Inc.
Mark Ahrens-Townsend




President and CEO
204-477-7592
204-474-7552 (FAX)


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  The DEA Finds Bug Killer and Unidentified Chemicals in Street Popular Synthetic Drug Flakka
Kane Biotech Announces Issuance of Common Shares in Payment of Outstanding Interest
Bereitgestellt von Benutzer: Marketwired
Datum: 25.06.2015 - 09:41 Uhr
Sprache: Deutsch
News-ID 1368547
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

WINNIPEG, MANITOBA


Phone:

Kategorie:

Alternative


Anmerkungen:


Diese Pressemitteilung wurde bisher 226 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Kane Biotech Announces Board Members
"
steht unter der journalistisch-redaktionellen Verantwortung von

Kane Biotech Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Kane Biotech Inc.



 

Who is online

All members: 10 565
Register today: 0
Register yesterday: 2
Members online: 0
Guests online: 81


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.